Details for New Drug Application (NDA): 209963
✉ Email this page to a colleague
NDA 209963 describes GOPRELTO, which is a drug marketed by Noden Pharma and is included in one NDA. It is available from two suppliers. There are twelve patents protecting this drug. Additional details are available on the GOPRELTO profile page.
The generic ingredient in GOPRELTO is cocaine hydrochloride. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the cocaine hydrochloride profile page.
The generic ingredient in GOPRELTO is cocaine hydrochloride. There are three drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the cocaine hydrochloride profile page.
Summary for 209963
| Tradename: | GOPRELTO |
| Applicant: | Noden Pharma |
| Ingredient: | cocaine hydrochloride |
| Patents: | 12 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 209963
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Medical Subject Heading (MeSH) Categories for 209963
Suppliers and Packaging for NDA: 209963
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| GOPRELTO | cocaine hydrochloride | SOLUTION;NASAL | 209963 | NDA | Genus Lifesciences Inc. | 64950-359 | 64950-359-04 | 1 BOTTLE, GLASS in 1 CARTON (64950-359-04) / 4 mL in 1 BOTTLE, GLASS |
| GOPRELTO | cocaine hydrochloride | SOLUTION;NASAL | 209963 | NDA AUTHORIZED GENERIC | Genus Lifesciences Inc. | 64950-362 | 64950-362-04 | 1 BOTTLE, GLASS in 1 CARTON (64950-362-04) / 4 mL in 1 BOTTLE, GLASS |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | SOLUTION;NASAL | Strength | 4% | ||||
| Approval Date: | Dec 14, 2017 | TE: | RLD: | Yes | |||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Feb 7, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | METHOD OF ADMINISTERING A LOCAL ANESTHETIC PRIOR TO PERFORMING A DIAGNOSTIC OR SURGICAL PROCEDURE ON A SUBJECT WITH HEPATIC OR RENAL IMPAIRMENT | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Feb 7, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | METHOD FOR THE INDUCTION OF LOCAL ANESTHESIA PRIOR TO PERFORMING A PROCEDURE ON, THROUGH, OR ADJACENT TO THE MUCOUS MEMBRANES | ||||||||
| Patent: | ⤷ Sign Up | Patent Expiration: | Feb 7, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | METHOD OF ADMINISTERING A LOCAL ANESTHETIC TO THE MUCOUS MEMBRANES | ||||||||
Complete Access Available with Subscription
